5 big biotech losers from JPMorgan's massive healthcare conference
The J.P. Morgan Healthcare Conference in San Francisco is a chance for healthcare companies to start the year off right.
Executives give high-stakes presentations to investors - and then meet with them privately - to try to convince them to invest in their companies. Often, companies will save up news to announce at the event, like clinical trial results that show a new drug is working, or good financial news.
But sometimes, the news is disappointing. That can send stocks plummeting and turn off investors. Or it can create openings for savvy investors to bet on companies at a cheap price.
These are the five biotech stocks that had big tumbles during the conference this week.
Subscribe to Business Insider's weekly healthcare newsletter Dispensed for all the biggest news from the J.P. Morgan Healthcare Conference.
- Ethical Hacking and Cybersecurity
- EAM Jaishankar meets Australian Intelligence chief Andrew Shearer on sidelines of Raisina Dialogue
- Sustainable Tourism Practices
- Byju's shareholders vote to remove CEO, family; company calls vote invalid
- Engaging with competent authorities, use only genuine cheese, says McDonald's